MYTELASE
LOE ApproachingNDAORALTABLET
Approved
May 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYTELASE is an oral small-molecule tablet approved in 1956 by Sanofi for an undisclosed indication. The specific mechanism of action and therapeutic area remain proprietary or legacy-classified in available data.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting a consolidating commercial footprint and reduced headcount trajectory.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MYTELASE has zero linked job openings, reflecting its legacy status and approaching loss of exclusivity. Career progression on this product is limited; opportunities exist primarily in defensive commercial and operational roles rather than innovation-focused positions.
Brand ManagerField Sales Representative
Worked on MYTELASE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.